Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request
Feb 04 2026
•
By
Sue Sutter
Two different views emerged within FDA about the approvability of Tavneos.
(Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Product Reviews
More from Asia